Riptide Bioscience President to Address AACR Conference

January 10, 2016

SAN FRANCISCO, CA. – Dr. George R. Martin, President of Riptide Bioscience, delivered an invited presentation to the American Association for Cancer Research (AACR) Special Conference on "The Function of Tumor Microenvironment in Cancer Progression," held in San Diego, California, on January 7 - 10, 2016.

Dr. Martin's presentation was entitled "Synthetic peptides suppress M2 macrophages and synergize with chemotherapy in prostate and breast cancer models." It summarized the body of in vitro and in vivo research on certain amphipathic peptides currently understood to restore the balance between canonically and alternatively activated macrophages in solid organ tumors.

Dr. Martin presented the findings of repeated in vivo studies that such peptides show synergy with Gemcitabine, Docetaxel, and other chemotherapeutic agents, reducing tumor growth and extending survival in a number of well-characterized animal models.

Dr. Martin is the former Scientific Director of the National Institute on Aging, and former Chief Scientific Officer of Fibrogen, Inc. (NASDAQ: FGEN). The invention of Matrigel and the discovery of laminin, lysyl oxidase, and procollagen were products of Dr. Martin's NIH laboratory.

This was the second consecutive year for which an AACR Special Conference was scheduled focusing on the tumor microenvironment, increasingly understood to play a significant role in tumor growth and metastasis.

Riptide Bioscience, with laboratories in Vallejo, California, maintains an intensive program of research into peptide compounds with potent antimicrobial and immunomodulatory activity. Contact:

Back to all news articles >